|AHFS/Drugs.com||International Drug Names|
|Oral, IM, IV|
|Metabolism||The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours|
|Elimination half-life||Half-life (1.4–4 hours)|
|Excretion||The drug is rapidly metabolized to the glucuronide, and mostly excreted in the urine|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||233.355 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
A partial μ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full μ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.
- US patent 4197239, Cavalla JF, Shepherd RG, White AC, "Hexahydroazepine, Piperidine and Pyrrolidine Derivatives", issued 1980-04-08, assigned to Wyeth
- Holmes B, Ward A (1985). "Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy". Drugs. 30 (4): 285–312. doi:10.2165/00003495-198530040-00001. PMID 2998723.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|